 To compare the efficacy of 3 s.c. doses of elsiglutide versus vs. placebo and vs. each other dose in the prevention of CID in colorectal cancer patients treated with 5-FU based chemotherapy FOLFOX or FOLFIRI with no addition of a monoclonal antibody. 